1. Home
  2. EML vs CRDL Comparison

EML vs CRDL Comparison

Compare EML & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastern Company (The)

EML

Eastern Company (The)

HOLD

Current Price

$20.05

Market Cap

119.2M

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$0.95

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EML
CRDL
Founded
1858
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.2M
97.3M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
EML
CRDL
Price
$20.05
$0.95
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
16.1K
353.8K
Earning Date
03-03-2026
03-27-2026
Dividend Yield
2.19%
N/A
EPS Growth
185.40
N/A
EPS
1.17
N/A
Revenue
$248,970,345.00
N/A
Revenue This Year
$19.05
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.61
$0.77
52 Week High
$26.76
$1.59

Technical Indicators

Market Signals
Indicator
EML
CRDL
Relative Strength Index (RSI) 60.54 39.86
Support Level $17.96 $0.94
Resistance Level $21.07 $1.09
Average True Range (ATR) 0.63 0.05
MACD 0.14 -0.01
Stochastic Oscillator 67.97 5.76

Price Performance

Historical Comparison
EML
CRDL

About EML Eastern Company (The)

The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: